Now that we know that Tedizolid is safe and displays less toxicity than its counterpart, if Tedizolid displays no improvement but equivalent efficacy does that mean bad news? I think that if its equivalent we should still have a drug to market and a different line of treatment for MRSA.
I think this JAMA article should be huge for this company right?
Help me out here. Equivalence or better in the P3 trial is good news right?
Hi rick, TSRX drug is given for less time (6 days vs. 10 days) and qd at a lower dose (more potent). TSRX drug can also kill some strains resistant to linezolid. Better on side effects - platelets, also. The new trial (Establish 2) is an IV / oral treatment protocol.